Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis

NCT00533091 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00533091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00533091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
October 31, 2010
Enrollment
51 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis or polymyositis